NEW YORK (GenomeWeb News) – A pair of investment banks today upgraded Affymetrix’s stock one day after a court found its principal rival Illumina guilty of infringing five of its patents.
News of the verdict, which forced Illumina to pay Affy $16.7 million in royalties for past sales, continued to buoy Affy’s shares, which were up 6.5 percent, or $1.70, at $28.31 in mid-afternoon trading today.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.